Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biobank

- PMLiVE

Roche announces launch of HPV self-sampling solution for cervical cancer screening

Around 342,000 die from cervical cancer worldwide, despite it being a preventable disease

- PMLiVE

Roche’s Vabysmo receives EC approval to treat two leading causes of vision loss

60% of people treated with Vabysmo were able to extend treatment to every four months

- PMLiVE

Roche launches digital PCR system to identify ultra-rare and emerging disease mutations

The diagnostics platform will allow researchers to divide DNA and RNA from an already extracted clinical sample into as many as 100,000 microscopic individual reactions

- PMLiVE

Roche’s Xofluza issued FDA approval to treat influenza in children aged five years and older

It is the first and only single-dose oral medicine for this indication in children as young as five

- PMLiVE

Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy

Pancreatic cancer is the third leading cause of cancer-related deaths, with over 430,000 deaths each year

- PMLiVE

Amgen to acquire ChemoCentryx in $3.7bn cash deal

The agreement includes the acquisition of ChemoCentryx’s autoimmune disease treatment Tavneos

- PMLiVE

Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection

Subcutaneously administering Tecentriq reduced the time needed for treatment compared to standard IV infusion

- PMLiVE

Roche’s Vabysmo recommended for EU approval by CHMP for sight loss

If approved, Vabysmo would be the first mechanism of action for nAMD and DME in the EU for over ten years

- PMLiVE

Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation

Alzheimer's affects more than 55 million people globally and is the most common form of dementia

- PMLiVE

Roche announces two-year data confirming Vabysmo improves neovascular age-related macular degeneration

The data showed, after two years, that 60% of patients treated with Vabysmo could be treated every four months, compared with 45% in year one

- PMLiVE

Roche’s Lunsumio granted Priority Review by FDA for people with relapsed or refractory follicular lymphoma

If approved, this could be the first such antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma

- PMLiVE

CureVac to acquire Frame Cancer Therapeutics in €32m deal

The acquisition will advance CureVac’s oncology strategy and offers the potential to develop off-the-shelf and personalised cancer vaccines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links